Red Biotechnology Market to to Grow with a CAGR of 10.67% through 2030
Rising
product development and genetic engineering for treatment of chronic diseases
are expected to drive Global Red Biotechnology Market in the forecast period,
2026-2030.
According
to TechSci Research report, “Red Biotechnology Market –Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2030F”, the Global Red
Biotechnology Market stood at USD 421.32 billion in 2024 and is anticipated to
grow with a CAGR of 10.67% in the forecast period through 2030. This can
be attributed to growing usage of red biotechnology in biopharmaceutical industry
for production of biologic drugs. Red biotechnology is applied in several
fields such as diagnostics, gene therapy, clinical trial and research and is
thereby creating lucrative opportunities for the growth of the Global Red
Biotechnology Market.
Meanwhile, other factors such as increased demand for red
biotechnology for combined vaccine production, increased tissue engineering
involved in production of artificial bones and skin, growing research and
advancement in stem cell research fields to produce new products and methods,
are anticipated to bolster the market growth in the forecast period.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on " Global Red Biotechnology Market”
Global Red Biotechnology Market is segmented
into product type, application, end-user, regional distribution, and company.
Based on Product Type, Gene Recombinant Drugs are expected
to register the fastest growth in the global Red Biotechnology Market. This
rapid growth is largely driven by breakthroughs in genetic engineering and the
increasing need for targeted, effective treatments for complex diseases such as
cancer, autoimmune disorders, and genetic conditions. Gene recombinant
drugs—biologically derived therapeutics created through recombinant DNA
technology—include monoclonal antibodies, cytokines, and therapeutic proteins
that offer high specificity and minimal side effects. Governments across the
globe are actively investing in genomics and recombinant drug development. For
instance, the U.S. National Institutes of Health (NIH) allocated over $3
billion in 2023 to genomic research and precision medicine initiatives, many of
which support the development of gene-based therapeutics. Additionally, the
European Medicines Agency (EMA) and the U.S. FDA have accelerated the review
and approval process for recombinant biologics through fast-track and orphan
drug designations. As more such therapies demonstrate efficacy in clinical
trials and gain regulatory approval, the recombinant drugs segment is projected
to grow at a robust pace over the coming years.
Based on the Region, Asia Pacific is expected to exhibit the
fastest growth in the global Red Biotechnology Market. This accelerated growth
is driven by increasing investments in healthcare infrastructure, rising
government support for biotechnology research, and growing demand for advanced
therapeutics to manage chronic and infectious diseases. Countries across the
region, including China, India, Japan, and South Korea, are significantly
expanding their biopharmaceutical manufacturing capabilities and fostering
innovation through national biotechnology strategies and funding initiatives.
In addition, the rising prevalence of genetic disorders, along with greater
adoption of personalized medicine and gene therapy solutions, is expected to
propel red biotechnology advancements in the region over the coming years.
Major companies operating in the Global Red Biotechnology
Market are:
- Pfizer,
Inc.
- Takeda
Pharmaceutical Company Limited
- Gilead
Sciences
- Regeneron
Pharmaceuticals, Inc.
- F.
Hoffmann-La Roche Ltd.
- Bruker
Corporation
- Merck
KGaA
- Celgene
Corporation
- Amgen
Inc.
- Biogen
Inc.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“The Global
Red Biotechnology Market is projected to witness robust growth driven by the
increasing adoption of biotechnological innovations in the development of
precision medicine and advanced genetic engineering solutions. The expanding
application of red biotechnology across areas such as gene therapy, vaccine
development, personalized diagnostics, and biopharmaceutical manufacturing is
significantly transforming modern healthcare practices. In addition to the
scientific advancements, the market is also being propelled by a steady rise in
regulatory approvals for novel biotherapeutics and the growing trend of
strategic mergers, acquisitions, and collaborations among key industry players.
Besides, increasing new product approvals and growing mergers and acquisitions
among the key players are further expected to support the market growth in the
region,” said Mr. Karan Chechi, Research Director of TechSci Research, a
research based global management consulting firm.
“Red Biotechnology Market – Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others), By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery and Others), By End-User (Pharmaceutical and Biotechnology Companies, CMO & CRO, Research Institute and Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Red
Biotechnology Market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Red Biotechnology
Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com